Ultrapar Participações S A : signs agreement to sell Oxiteno

ULTRAPAR PARTICIPAÇÕES S.A.

MATERIAL NOTICE

Ultrapar signs agreement to sell Oxiteno

São Paulo, August 16, 2021 - Ultrapar Participações S.A. (B3: UGPA3 / NYSE: UGP, "Ultrapar" or "Company"), in accordance with CVM Instruction Nr. 358/02, announces the signing of a share purchase agreement for the sale of all shares of Oxiteno S.A. - Indústria e Comércio ("Oxiteno") to Indorama Ventures PLC (SET: IVL, "Indorama"). The total sale price (enterprise value) is US$ 1,300 million, of which US$ 1,150 million at closing, subject to customary adjustments, such as changes in working capital and net debt position, and US$ 150 million in the second anniversary after closing.

Following the announcements of the divestment of Extrafarma and ConectCar, the sale of Oxiteno is aligned with the portfolio review that Ultrapar has been communicating to its shareholders and the capital markets. With a more complementary and synergistic holdings, Ultrapar concludes the phase of its portfolio rationalization and will now concentrate on developing investment opportunities in the verticals of energy and infrastructure, with increasing focus on energy transition, leveraged by its portfolio and expertise.

Indorama and Oxiteno have synergies in the integrated oxides and derivatives business, specifically in the downstream surfactants portfolio. In addition to Oxiteno's strong position in Latin America, the transaction gives Indorama access to innovative platforms in attractive end markets and technologies, enhanced geographical diversification, and strong innovation capabilities. The combined business creates a major ethoxylates producer in the Americas and the second largest globally.

"Oxiteno's outstanding position in Brazil and Latin America was built and has been developed by Ultrapar for more than 40 years. We are glad we managed to reach this agreement with a strategic player with global leadership position and relevant synergies, which allowed us to achieve an accretive valuation." said Mr. Frederico Curado, CEO of Ultrapar.

The completion of this transaction is subject to usual conditions precedent in deals of this type, including approval by the Brazilian antitrust authority and American Federal Trade Commission. Preemptive rights will be granted to Ultrapar's shareholders who wish to acquire Oxiteno's shares, proportionally to their respective stake in Ultrapar's share capital and for the same price per share to be paid by Indorama, pursuant to article 253 of the Brazilian Corporate Law. The shareholders of Ultrapar that exercise such right will become direct shareholders of Oxiteno, a privately held company with limited liquidity. Ultrapar will call a general shareholders' meeting promptly to formalize the offering of the aforementioned preemptive rights, detailing the procedures for its exercise, as applicable.

Oxiteno will maintain its regular and independent course of business until the closing of the transaction.

Ultrapar will host a conference call for investors and analysts on this date at 9am BRT (8am EDT) to comment on the transaction. The access link and dial-in numbers will be sent through the IR mailing list.

Rodrigo de Almeida Pizzinatto

Chief Financial and Investor Relations Officer

Ultrapar Participações S.A.

Bank of America and BMA Advogados acted as financial advisor and legal advisor, respectively, in this transaction.

This material notice should not be construed as an offer to sell or solicitation of an offer to purchase securities issued by Ultrapar or Oxiteno, or an offer, solicitation or sale of securities issued by Ultrapar or Oxiteno in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

The right of first refusal in relation to the shares issued by Oxiteno has not been, and will not be, registered under the Securities Act of 1933, as amended ("Securities Act") or any other U.S. federal or state securities laws, and such securities may not be offered, sold, pledged or otherwise transferred in the United States or to U.S. persons, unless such offer or sale is exempt from, or not subject to, registration under the Securities Act and any applicable securities laws of the states of the United States.